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Abstract 
Background: Affective and emotional dysregulation symptoms such as depression, anxiety, 
euphoria and irritability are common neuropsychiatric symptoms (NPS) in pre-dementia 
states such as Mild Cognitive Impairment (MCI), and are also present in cognitively normal 
older adults. These symptoms comprise one of the domains in the construct of Mild 
Behavioral Impairment (MBI), which describes their emergence in later life as an at-risk 
state for cognitive decline and dementia, and as a potential manifestation of prodromal 
dementia. This selective scoping review explores the epidemiology and neurobiological links 
between affective and emotional symptoms in later life, and incident cognitive impairment 
and all-cause dementia, focusing on the newer literature in this very rapidly expanding field 
of research. 
Method: A review of existing literature on depression, anxiety, euphoria and irritability in 
prodromal and dementia states, focusing on epidemiology and neurobiology. Search terms 
used included: “cognitive impairment”, “mild cognitive impairment”, “dementia”, 
“prodromal dementia”, “preclinical dementia”, “Alzheimer’s”, “depression”, “dysphoria”, 
“mania”, “euphoria”, “bipolar disorder”, and “irritability”. 
Results: Symptoms of affective and emotional dysregulation are common in preclinical and 
prodromal dementia syndromes and are often harbingers of neurodegenerative change and 
progressive cognitive decline. Nosological constraints in distinguishing between chronic or 
pre-existing psychiatric symptomatology, and later life acquired NPS limit somewhat the 
utility of historical data, but a plethora of emerging research is emphasizing the importance 
of addressing the time frame between symptom onset and cognitive decline, as well as the 
age of onset of symptoms.  
Conclusion: Further study of the MBI affective and emotional dysregulation symptom 
domain is needed. While such symptoms are of prognostic utility, there are limited 
interventions to treat these symptoms and prevent the ensuing dementia syndromes. Trials 
will need to assess response separately for interventions targeting traditional dementia 
pathology, towards novel pathology, as well as using traditional psychiatric medications. 
Research focusing explicitly on later life onset symptomatology will improve our 
understanding of the neurobiology of NPS and neurodegeneration, enrich the study sample, 
and inform observational and clinical trial design for prevention and treatment strategies for 
at-risk individuals. 
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Background 
The role of emergent neuropsychiatric symptoms (NPS) as a risk factor for all-cause 
dementia is increasingly being recognized. Evidence links NPS in advance of dementia to a 
greater likelihood of cognitive impairment (Mortby et al., 2017) and cognitive decline (Geda 
et al., 2014) compared to those without NPS. Affective and emotional dysregulation 
symptoms are amongst the most common NPS presenting in mild cognitive impairment 
(MCI) (Peters et al., 2012), and are, along with other NPS, associated with poorer outcomes 
overall (Cerejeira et al., 2012) and higher conversion rates from MCI to dementia (Palmer et 
al., 2007). 
 
While the early presentation of NPS in the course of neurodegenerative disease has 
traditionally raised suspicion of behavioral variant frontotemporal dementia (bvFTD), 
evidence also suggests that NPS can emerge in advance of any dementia syndrome (Taragano 
et al., 2009). Historically, these symptoms have been viewed through the lens of psychiatric 
nosology with insufficient attention given to their late life onset and consequently their 
frequent misclassification as idiopathic psychiatric illness (Woolley et al., 2011), potentially 
exposing patients to inappropriate medications or delays in dementia diagnosis (Jalal et al., 
2014). Cognitive patterns alone may not adequately differentiate between psychiatric and 
neurodegenerative disease (Ting et al., 2010). 
 
Mild Behavioral Impairment (MBI) is characterized by later life acquired, sustained and 
impactful NPS of any severity that cannot be better accounted for by other formal medical 
and psychiatric nosology. MBI is an “at risk” state for incident cognitive decline and 
dementia, and for some, MBI is the index manifestation of neurodegeneration, observed in 
advance of cognitive impairment (Ismail et al., 2016). Importantly, MBI distinguishes 
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between chronic psychiatric symptomatology and formal psychiatric illness, vs. new onset 
psychiatric symptoms in older adults, the latter of which are core to the MBI construct of the 
at-risk state. MBI has been formally described in the International Society to Advance 
Alzheimer’s Research and Treatment – Alzheimer’s Association (ISTAART-AA) MBI 
proposed research diagnostic criteria, which classify MBI into the domains of decreased 
drive/motivation, affective/emotional dysregulation, impulse dyscontrol and agitation, social 
inappropriateness, and delusions and hallucinations (Ismail et al., 2016). Assessment of MBI 
has been operationalized with the development of the MBI checklist (MBI-C), which was 
tailored specifically to the MBI criteria, including explicit observations of symptoms being 
later life in onset, and sustained for 6 months - these requirements are not explicit in many 
NPS rating scales (Ismail et al., 2017a). The affective/emotional dysregulation domain is a 
core feature of MBI, and includes symptoms of anxiety, depression and dysphoria, euphoria, 
and irritability. In this review we will explore the epidemiology and neurobiological links 
between affective and emotional symptoms and incident cognitive impairment and all-cause 
dementia. 
 
Depression and dysphoria 
Increasing evidence in both cognitively normal (CN) older adults (without objective 
cognitive impairment) and in MCI suggests that emergent depression is a risk factor for 
dementia (Rosenberg et al., 2013) and may constitute a prodrome (Ismail et al., 2014). This is 
true for both Alzheimer’s disease (AD) dementia and all-cause dementia (Barnes et al., 2012; 
Geda et al., 2014; Steenland et al., 2012). In a meta-analysis of 57 MCI studies, depression 
was found to be common, with a prevalence of 25% in community samples and 40% in 
clinical samples (Ismail et al., 2017b), and associated with increased risk of progression to 
AD dementia (Hermida et al., 2012; Lopez-Anton et al., 2015). Another recent study 
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assessed the association of subsyndromal depression (SSD) with cognitive decline over 4 
years in a sample of MCI patients from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI). Compared with individuals without depressive symptoms, the SSD group exhibited 
accelerated decline on cognitive measures (Gonzales et al., 2017). This suggests that in early 
stages of AD, depressive symptoms may be clinical indicators of AD pathology and/or 
impact AD pathogenesis (Donovan et al., 2014; Geda et al., 2014; Gonzales et al., 2017; 
Steenland et al., 2012).  
Very recent research has moved the field rapidly forward, and underscored the importance 
of incipient depressive symptoms in emergence of dementia syndromes. A 28-year follow up 
of a 10,189 person cohort from the United Kingdom described the emergence of sustained 
depressive symptoms to increase the risk of incident dementia, but longstanding sustained 
depressive symptoms offered no increased risk (Singh-Manoux et al., 2017). A 14-year 
longitudinal Australian study of 4,922 cognitively intact men demonstrated that depression is 
more likely to be a marker of incipient dementia than a truly modifiable risk factor due to a 
time-dependent link between onset of depression and incidence of dementia. The association 
between depression and dementia was only apparent during the initial 5 years of follow-up, 
and was not observed if depression emerged more than 5 years before the onset of dementia 
(Almeida et al., 2017). Similarly, a Finnish nationwide nested case-control study of 27,948 
pairs also established the importance of the time window between psychiatric symptoms and 
dementia. Hospital treated behavioral and mental disorders, including depression and other 
mood disorders, were associated with a higher risk of AD in the 5-year but not the 10-year 
time window (Tapiainen et al., 2017). The authors suggested that some of these disorders 
may have represented misdiagnosed prodromal symptoms of AD. This highlights the 
importance of proper differential diagnostics among older persons and the importance of 
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appropriate time window in psychiatric and neuroepidemiology research (Tapiainen et al., 
2017). 
 
Despite converging evidence for the relationship between depression and dementia, the 
neurobiology of depressive symptoms in preclinical dementia syndromes has not been clearly 
established. According to one hypothesis, which enjoys some empirical support, clinically 
significant symptoms of major depressive disorder and subclinical depressive symptoms, in 
preclinical and prodromal AD, may indicate AD pathological changes in selectively 
vulnerable brain regions. In CN older adults, clinically significant depressive symptoms have 
been associated with AD-related changes: thinning of the entorhinal cortex, hippocampal 
volume reduction, and decreased CSF amyloid-beta 42 (Ballmaier et al., 2008; Gerritsen et 
al., 2011; Pomara et al., 2012). A cross-sectional study in late life major depression found 
reduced hippocampal volume in depressed vs. control participants but no differences in 
cortical amyloid (measured in vivo by positron emission tomography (PET) imaging) (De 
Winter et al., 2016). In the aforementioned ADNI sample of participants with SSD and MCI, 
frontal and anterior cingulate atrophy was associated with global cognitive decline. These 
regions were postulated to govern cognitive decline in this highly vulnerable population 
(Gonzales et al., 2017). 
 
Studies of subclinical depressive symptoms in CN older adults and across the AD 
spectrum have similarly shown associations with underlying structural and functional 
changes and more variably, with AD proteinopathies, A-beta and tau (Babulal et al., 2016; 
Donovan et al., 2015; Gatchel et al., 2017; Krell-Roesch et al., 2016; McCutcheon et al., 
2016). Donovan and colleagues, in a cross-sectional study of CN older adults, found that 
subclinical depressive symptoms on the Geriatric depression scale (GDS) were associated 
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with lower hippocampal volume, while GDS symptom clusters grouping with dysphoria, 
apathy and anhedonia were associated with decreased hippocampal volume and reduced 
cerebral 18F-fluorodeoxyglucose (FDG) metabolism (for apathy-anhedonia symptoms); these 
associations were independent of cortical amyloid burden (Donovan et al., 2015). Similarly, 
Babulal and colleagues, assessing subclinical positive and negative affective symptoms by 
the GDS and other measures, found a longitudinal but not cross-sectional association between 
GDS and cerebrospinal fluid (CSF) and amyloid (Pittsburgh Compound B (PiB)) PET AD 
biomarkers (Babulal et al., 2016). In contrast, clinico-pathologic studies in mixed populations 
of CN and AD participants (Wilson et al., 2003; Wilson et al., 2014) and in MCI and mild 
AD participants (McCutcheon et al., 2016) have not shown robust relationships between 
depressive symptoms and amyloid plaques or neurofibrillary tangles (McCutcheon et al., 
2016; Wilson et al., 2003; Wilson et al., 2014). Together, these findings suggest that the 
neurobiology of depressive symptoms may differ based on depressive symptom severity and 
disease stage, and may not be mediated solely by AD proteinopathies.  
 
In addition to AD, converging evidence supports depression as a risk factor and/or 
prodrome for vascular dementia (Barnes et al., 2012; Lin et al., 2016). Depressive symptoms 
may be more common in vascular dementia than in AD dementia (O'Brien, 2003), and 
depression has been associated with amnestic (Geda et al., 2014; Steenland et al., 2012) as 
well as both amnestic and non-amnestic MCI (Hermida et al., 2012). The robust relationship 
between cerebrovascular disease and depressive symptoms may underlie this association 
(Alexopoulos et al., 1997; Krishnan et al., 1997). In particular, disruption of fronto-
subcortical circuits, whether by vascular lesions or in FTD, is one mechanism hypothesized 
to underlie the association between depression and vascular and FTD pre-dementia 
syndromes. 
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Anxiety 
There has been a growing body of research supporting an association between anxiety and 
reduced cognitive function in older adults, indicating clinically elevated anxiety symptoms to 
be associated with poorer global cognition, episodic memory and executive functioning 
(Beaudreau and O'Hara, 2008). Anxiety symptoms are commonly associated with 
neurodegenerative diseases, and prevalence estimates range between 8%-71% (Seignourel et 
al., 2008). Clinically elevated anxiety has also been linked to cognitive decline in older adults 
(DeLuca et al., 2005; Gallacher et al., 2009; Sinoff and Werner, 2003), leading some to 
conclude that anxiety symptoms may predict cognitive decline in older adults without 
dementia (Pietrzak et al., 2012). Anxiety symptoms are common in MCI (Apostolova and 
Cummings, 2008; Spalletta et al., 2010), and co-morbid presentation of anxiety in MCI has 
been shown to increase the risk of progressing to AD (Mah et al., 2015; Palmer et al., 2007; 
Palmer et al., 2010; Rabins et al., 2013).  
 
Systematic reviews and meta-analyses are less conclusive, however, with some providing 
support for anxiety as a risk factor for dementia (Gulpers et al., 2016), while others provide 
mixed results (Cooper et al., 2015). For instance, Gulpers et al. (2016) conducted a 
systematic review and meta-analysis of 20 studies demonstrating anxiety predicts incident 
cognitive impairment (relative risk [RR]: 1.77, 95% CI: 1.02-2.42, z=2.05, p=0.040) in the 
community, with greater age being a driver of results, suggesting anxiety to be a prodromal 
symptom. However, co-morbid anxiety in subject with MCI seen in the clinical setting did 
not predict conversion to dementia in this study (RR: 1.21, 95% CI: 0.90-1.63, z=1.28, 
p=0.200) (Gulpers et al., 2016). Conversely, Cooper et al. (2015) provided mixed results, 
identifying only one higher quality epidemiological study that showed anxiety to predict 
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Alzheimer’s disease (Palmer et al., 2007), while in three clinical studies (Devier et al., 2009; 
Robert et al., 2006; Rozzini et al., 2007) anxiety was found not to predict conversion (pooled 
odds ratio [OR] from clinical studies: -0.11, -0.34 to 0.11). Nonetheless, a recent meta-
analysis by Li and Li (2017) of 11 studies showed a pooled hazard ratio of conversion to 
dementia for co-morbid anxiety and MCI compared to those without anxiety (hazard ratio 
(HR): 1.18, 95% CI: 1.07-1.31, p=0.002). Heterogeneity was substantial in these studies, and 
confounding the results is the fact that rating scales used to assess anxiety did not reliably 
distinguish between anxiety as part of a psychiatric illness, or anxiety as a new-onset 
phenomenon, with little information to determine whether psychiatric symptoms were brief 
and episodic, or sustained symptoms representing a change from baseline state. 
 
While the manifestations of anxiety in prodromal patients are still under investigation, 
worried appearance, fearfulness, tension, restlessness and fidgeting are all common 
manifestations of anxiety in people with dementia (Ferretti et al., 2001). What remains 
unclear, is the degree to which anxiety symptoms reflect a psychopathological reaction to 
cognitive and functional decline, or whether they arise from biological changes in emotion-
relevant neural circuits (Levenson et al., 2014). Levenson et al. (2014) conclude that there is 
strong evidence to support the latter, based on findings of heightened intrinsic connectivity in 
the salience networks in AD (Balthazar et al., 2013) and hypo-metabolism in the medial 
temporal lobe, superior temporal gyrus and insula (Hashimoto et al., 2006), both which have 
been linked to increases in anxiety. Further evidence comes from the National Alzheimer 
Coordinating Center (NACC) registry in a study of 2416 cognitively normal participants over 
the age of 50 assessing NPS and conversion from a Clinical Dementia Rating Scale (CDR) of 
0 to >0 (Masters et al., 2015). The Hazard Ratio of conversion in participants with anxiety 
was 2.83 (CI: 1.93-3.19) compared to those without anxiety. Additionally, the authors 
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described a 3-phase progression of NPS within those with cognitive decline: first, irritability, 
depression, and nighttime behavior changes; next, anxiety, appetite changes, agitation, and 
apathy; and last, elation, motor disturbances, hallucinations, delusions, and disinhibition, 
suggesting anxiety to be an emerging phenomenon with progressive neurodegeneration 
(Masters et al., 2015). Findings from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) have further provided mechanistic evidence linking NPI-Q measured anxiety 
symptoms in amnestic MCI and conversion to Alzheimer’s disease (AD) (Mah et al., 2015). 
Mah and colleagues found that anxiety, over and beyond depression or memory decline 
predicted a greater decline in entorhinal cortex volume (Mah et al., 2015). However, it was 
not unequivocally determined in this study whether anxiety symptoms were causative, 
mediating, or a consequence of neurodegeneration. 
 
A number of potential hypotheses for a causal pathway between anxiety and cognitive 
impairment have been described including: a) hypercortisolism, b) cardiovascular disease, c) 
low-grade inflammation, d) brain-derived neurotrophic factor suppression, and e) depletion of 
cognitive reserves (as reviewed in Gulpers et al., 2016). According to the hypercortisolism 
hypothesis, anxiety is a state of heightened stress and thus higher cortisol levels. Cortisol 
levels are in turn related to symptom severity and poorer outcomes on neuropsychological 
tests (Erickson et al., 2003; Leininger and Skeel, 2012; Mantella et al.; Rosnick et al., 2013). 
Further, cortisol-induced overstimulation of glucocorticoid receptors in the medial temporal 
lobe have also been linked to hippocampal atrophy (Erickson et al., 2003; Sapolsky, 2000), 
and stress has been postulated as a mechanism for hippocampal injury and volume loss 
(Sheline et al., 1999). Animal studies have shown higher cortisol administration levels to 
increase amyloid and tau accumulation, both processes involved in AD pathology (Green et 
al., 2006). Anxiety has also been linked to coronary artery disease and stroke, with anxiety 
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implicated in the triggering of physiological reactions (e.g. increased heart rate, blood 
pressure, vasoconstriction, platelet activity) that are associated with cardiovascular disease 
and ultimately vascular dementia (Batelaan et al., 2016; Lambiase et al., 2014; Sheps and 
Sheffield, 2001). Chronic low-level inflammation is another related causal hypothesis, in 
which elevated cytokines such as interleukin-6 and tumor necrosis factor are observed in 
stress-related states such as anxiety, and in turn shown to be linked to negative effects on 
cognitive functioning (Furtado and Katzman; Reichenberg et al., 2001). Furthermore, anxiety 
disorders have also been linked to decreased brain derived neurotrophic factor (BDNF) levels 
or polymorphisms (Domingos da Silveira da Luz et al., 2013). BDNF is needed for synaptic 
plasticity, learning and memory, and neuronal repair and is decreased in AD and MCI 
(Teixeira et al., 2010). BDNF signalling is necessary for antidepressant response, and BDNF 
deletion attenuates this response (Castrén and Kojima, 2017). The Framingham Heart Study 
identified higher stratified BDNF levels as a protective factor for dementia, emphasizing its 
importance as a marker and target (Weinstein et al., 2014). Finally, it has been proposed that 
chronic and recurrent anxiety disorders throughout the life-course may lead to avoidance 
behaviors which in turn may result in lowered cognitive reserve as a result of less mental and 
social stimulation, therefore increasing the risk of dementia (Stern, 2012).  
 
 
Elation, Euphoria and Mania 
A constellation of elation, euphoria and mania can represent a pre-dementia syndrome. 
“Secondary mania”, mania due to an etiology other than bipolar disorder, causes the majority 
of new onset mania in older adults (Brooks and Hoblyn, 2005; Krauthammer and Klerman, 
1978), which include neurodegenerative disorders, such as pre-dementia syndromes and 
dementias (Brooks and Hoblyn, 2005; Krauthammer and Klerman, 1978). 
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Evidence from cohort studies as well as retrospective data suggests that those with late 
onset mania are at an increased risk for development of cognitive impairment and dementia. 
Patients who develop their first manic episode after age 58 have higher rates of cognitive 
impairment, which is variably reversible (Brooks and Hoblyn, 2005; Young and Klerman, 
1992). A large cohort study of 37,768 men ages 65 to 85 with bipolar disorder had an 
adjusted hazard ratio of 2.3 (HR=2.30, 95% CI 1.80-2.94) for development of dementia 
(Almeida et al., 2016). Subgroups who developed bipolar disorder over the age of 70 or 
within the past 5 years had the greatest risk for development of dementia (Almeida et al., 
2016), very similar to the evidence for depressive symptoms (Almeida et al., 2017). A 
retrospective case series of patients over the age of 65 admitted for mania, found 22 of 92 
(24%) had evidence of cerebral organic impairment (Almeida et al., 2016; Stone, 1989). 
Another case series showed that 8 of 25 (32%) older adults with mania went on to develop 
cognitive impairment within 5 to 7 years (Dhingra and Rabins, 1991). 
 
Cognitively normal individuals with symptoms of elation may be at elevated risk of 
developing AD. A survival analysis of 11,453 cognitively normal individuals from the NACC 
database, showed that positive ε4 carrier status and symptoms of elation, among other NPS, 
conferred greater risk of development of AD (Burke et al., 2016). Another NACC database 
study showed those with amnestic MCI had higher rates of elation and aggression as 
compared to non-amnestic MCI (Apostolova et al., 2014). However, symptoms of elation, 
euphoria and mania are relatively rare in AD type dementia as compared to FTD, with an 
estimated prevalence of 2.2% to 3.5% (Burns, 1992; Lyketsos et al., 1995).  
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The pathophysiology of late onset bipolar disorder is thought to be different from early 
onset bipolar disorder with the late onset group having higher rates of neurologic and 
vascular brain abnormalities (Fujikawa et al., 1995; Sami et al., 2015; Tohen et al., 1994; 
Young and Klerman, 1992). Vascular mania has been suggested as a subtype of secondary 
mania, when it occurs in the presence of co-morbid cerebrovascular disease or cognitive 
impairment (Sajatovic et al., 2015; Steffens and Krishnan, 1998). The association of 
cerebrovascular disease with late onset mania implies a possible prodrome to vascular 
dementia. Lesions in a number of different brain regions have been associated with the 
development of secondary mania including bilateral orbitofrontal, right temporoparietal, right 
basal and medial temporal lobe, basal ganglia, thalamic and right frontotemporal (Bakchine et 
al., 1989; Brooks and Hoblyn, 2005; Cerami et al., 2011; Danel et al., 1989; Robinson, 1997; 
Starkstein and Robinson, 1997; Turecki et al., 1993). A case control series by Ramírez-
Bermúdez showed that when compared to healthy normal adults, a group with first onset 
mania after age 50, had higher rates of white matter hyperintensities in the right frontal and 
the left temporal brain regions (Ramirez-Bermudez et al., 2016). A number of scientists 
hypothesize that damage to the right orbitofrontal region is a unifying finding in the 
development of secondary mania (Brooks and Hoblyn, 2005; Starkstein and Robinson, 1997). 
Disruption to orbitofrontal neurocircuitry appears common to both to secondary mania and 
bvFTD. More recently, two cases of sporadic FTLD with the same progranulin mutation and 
one case of FTLD with a C9ORF72 gene hexanucleotide expansion mutation developed 
symptomatology meeting criteria for a bipolar disorder diagnosis prior to clinical presentation 
of FTLD (Cerami et al., 2011; Floris et al., 2013). There have also been case reports of 
bipolar disorder mimicking BvFTD, with failure to progress to “probable” BvFTD after 3 to 
7 years of observation (Dols et al., 2016). 
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Irritability 
Irritability is common among neurobehavioral symptoms in neurodegenerative disease and 
causes increased burden on patients, caregivers and the community alike (Sousa et al 2016). 
Among cognitively impaired non-demented individuals in the Cache County cohort, 
irritability/ lability was, among all NPI domains, second only to depression/ dysphoria in 
prevalence (Peters et al., 2013). Irritability was the third most prevalent NPS regardless of 
dementia in a population–based longitudinal study of aging conducted in England and Wales, 
with sleep problems more prevalent in non-demented elders and apathy more prevalent in 
demented elders (Savva et al., 2009). It has now been shown that irritability is among the 
neurobehavioral symptoms which portends more rapid decline in several datasets including 
NACC (Forrester et al., 2016; Leoutsakos et al., 2015); the Spanish ZARADEMP cohort 
(Lobo et al., 2008) and the Mayo Clinic Study of aging (Geda et al., 2014). Hence, as with 
other emergent behavioral symptoms, monitoring emergent irritability in the clinic would 
seem of the utmost importance. 
 
Whether emergent irritability observed in the dementia prodrome should be regarded as a 
manifestation of a mood disturbance or one of behavioral dysregulation / disinhibition is 
unclear phenomenologically as there is support for both possibilities from cluster analyses 
(Leoutsakos et al., 2015). It might be hoped that studies of the neurobiology of irritability 
would ultimately serve to clarify this question thereby offering improved treatment strategies. 
However such studies have suffered from this ambiguous phenomenology as well. 
Disinhibition together with emotional lability in dementia has been associated with 
orbitofrontal-subcortical circuit dysfunction (Tascone and Bottino, 2013). The same can be 
said when irritability falls within agitation in AD. i.e. even with AD, associations have been 
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made with deficits in frontal, anterior cingulate and posterior cingulate cortices as well as the 
amygdala and hippocampus (Rosenberg et al., 2015). A specific association between 
irritability on the NPI scale has been made with lower fractional anisotropy of the anterior 
cingulate in a sample of MCI and AD patients (Tighe et al., 2012). On the other hand, when 
irritability is grouped with affective symptoms (depression) or psychosis, no clear evidence 
for specific neurobiological substrates emerges (Tascone and Bottino, 2013). Recently, 
however, an FDG-PET study in AD demonstrated that irritability had common metabolic 
changes to agitation (right temporal, right frontal, bilateral middle and posterior cingulate 
gyri) but differed in specific regions (right insular, precentral and postcentral gyri) 
(Weissberger et al., 2017), reflecting neurodegeneration in regions associated with core AD 
pathology (Rosenberg, 2017). It is noteworthy that to date, most of the work on the 
neurobiology of irritability comes from the dementia literature with little data addressing 
emergent irritability in the predementia stages in spite of its prevalence. That said, a very 
recent ADNI study of biomarker positive preclinical AD participants (amyloid and tau 
positive, MMSE ~29,) assessed relationships between NPS and 2-year interval change in 
metabolism measured by FDG-PET. Sleep behaviour and irritability predicted posterior 
cingulate hypometabolism at 2 years, “supporting the emerging conceptual framework in 
which NPS constitute an early clinical manifestation of AD pathophysiology” (Ng et al., 
2017). 
 
Conclusions/Future Directions 
Symptoms of affective and emotional dysregulation, ranging from depression and 
dysphoria, anxiety and worry, to elation, euphoria and irritability, are common in preclinical 
and prodromal dementia syndromes, and are often harbingers of progressive cognitive decline 
(Almeida et al., 2017; Donovan et al., 2014; Geda et al., 2014; Gonzales et al., 2017; Ismail 
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et al., 2016; Pietrzak et al., 2012; Singh-Manoux et al., 2017; Tapiainen et al., 2017). This 
spectrum of symptoms is associated with functional impairment and decreased cognitive and 
psychosocial function (Karttunen et al., 2011), and has prognostic utility in cognitively 
normal older adults and in MCI for several dementia sub-types (Barnes et al., 2012; Geda et 
al., 2014; Steenland et al., 2012). It remains important to clarify, however, whether the 
affective and emotional dysregulation symptoms have quantitative (i.e. severity of symptoms) 
vs. qualitative (i.e., a particular pattern of symptoms) relationships to dementia risk and 
progression. In an ADNI study of SSD, the chronic SSD group exhibited accelerated decline 
on measures of global cognition, memory, processing speed, and semantic fluency, as well as 
accelerated frontal lobe and anterior cingulate atrophy, compared to the non-depressed group 
(Gonzales et al., 2017). Thus, in this sample chronicity of low-grade symptoms, as opposed 
to severity, was associated with cognitive decline. 
 
However, DSM (and the aforementioned ADNI Gonzales et al. study) is silent on natural 
history of symptoms (i.e. chronic vs. new-onset), and the signal may thus be muddied by a 
heterogeneous population with varied symptom natural history. The MBI construct is 
predicated on the emergence of symptoms in later life as distinct and discrete from chronic 
and recurrent psychiatric illness with recurrent late life episodes. Overall, we believe that 
context is required to determine if symptom pattern or symptom severity (or both) reflect 
underlying neurobiology. For example, the recent paper by Almeida et al. (2017) described a 
graded association between severity of depressive symptoms and the risk of dementia, but 
that depressive symptoms were often a prodromal manifestation of dementia, as opposed to a 
chronic, recurrent depressive syndrome. In contrast, Rosenberg et al. (2013) determined that 
severity was not a predictor of cognitive decline in the NACC cohort. Further studies in this 
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area are required that emphasize the age of onset, severity, and qualitative pattern of 
symptoms. 
 
The neurobiology of affective symptoms in pre-dementia syndromes is varied and poorly 
understood. Converging data point toward underlying changes in brain structure and function 
in selectively vulnerable regions, and accumulation of disease specific pathology (i.e. 
proteinopathies and/or cerebrovascular lesions) (Babulal et al., 2016; Ballmaier et al., 2008; 
Donovan et al., 2015; Gerritsen et al., 2011; Krell-Roesch et al., 2016; Pomara et al., 2012). 
Previous work has largely involved investigating the neurobiology and prognostic utility of 
affective symptoms in the context of standard psychiatric diagnostic criteria, rather than study 
of endophenotypes and clusters of symptoms. This is in part due to the lack, until recently, of 
rating scales to capture early mild behavioral disturbances. As demonstrated in this review, 
the lack of adequate measures to assess symptoms of anxiety, depression and dysphoria, 
euphoria, and irritability in pre-clinical disease states and that specify late life onset and 
persistence, has impeded conclusive evidence with regards to the role of these NPS as a risk 
factor for cognitive impairment and dementia. Certainly, robust evidence from several large 
longitudinal and case-control epidemiological studies has highlighted the need for a 
determination of the age of onset of symptoms and of the time-window between onset of 
symptoms and decline in cognition to properly ascertain risk (Almeida et al., 2017; Singh-
Manoux et al., 2017; Tapiainen et al., 2017). The Mild Behavioral Impairment Checklist 
(MBI-C) (Ismail et al., 2017a) (available at www.MBItest.org) has specifically been 
developed to address this need, in order to systematically study NPS in pre-clinical states to 
determine their prognostic utility for cognitive decline and dementia.  
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Diverse symptoms of affect and emotional dysregulation commonly co-occur in older 
adults and can be challenging to systematically describe outside of the context of classic 
psychiatric diagnostic framework and phenomenology. Both the emotional dysregulation 
domain and the MBI-C as a whole comprehensively capture this spectrum of symptoms and 
thus provide an operationalized way to assess and track them (Ismail et al., 2017a). Further, 
the structure of the checklist provides the opportunity to differentiate the prognostic utility of 
this domain as a whole as well specific symptoms within it such as anhedonia, dysphoria, 
sadness, and anxiety (Ismail et al., 2017a). 
 
Adding to this complexity, the neurobiology of symptoms of affective and emotional 
dysregulation may differ in cognitively normal older adults compared to MCI, based on 
severity of the affective symptoms and the specific pre-dementia syndrome, and also in cases 
where symptoms are superimposed on a life-long recurrent affective or anxiety disorder. 
Future prospective studies of emotional dysregulation symptoms using the MBI framework in 
the clinical scenarios above are needed to further disentangle their prognostic utility and 
neurobiology. Studies will need to distinguish NPS reflecting core 'typical' mechanisms of 
neurodegeneration vs. those reflecting novel pathways, as such distinction carries 
implications for treatment.  If NPS are a manifestation of typical neurodegenerative 
pathology, then treatment would involve agents that modify that same pathology.  However, 
if NPS are manifestations of alternative pathology, interventions will be required for those 
alternative pathologies to modify outcome and course. The inconsistencies in the evidence 
stem, in part, from the inconsistencies in assessing natural history of symptoms i.e. chronic 
and recurring NPS versus new onset or emerging NPS. As the evidence base grows, the field 
will be able to better determine mechanisms, and distinguish between these two groups and 
their prognostic differences (if any). In addition to mechanistic studies, we suspect that 
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intervention studies will concurrently illuminate this area, and provide further evidence on 
the mechanisms above. 
Overall, while study and understanding of affective symptoms in MBI remains in early 
stages (say, compared to the understanding of MCI), new evidence is constantly emerging 
and informing the field that has importance implications for prevention and treatment. For 
example, the aforementioned paper by Almeida et al. (2017) describes a lack of 
antidepressant effect to decrease dementia incidence. In contrast, the paper in Neurology 
2009 by Lu et al. describes donepezil delaying progression from MCI to dementia in MCI 
participants with depressive symptoms. However, if treating NPS is the same as treating AD, 
then why are participants with significant NPS excluded from dementia clinical trials? In fact, 
should older adults with NPS be preferentially screened for dementia, and included in disease 
modifying trials? More studies are required to answer these questions, and the binary division 
into NPS vs. dementia is likely inadequate, requiring additional variables to ascertain risk and 
suitability for trial enrolment, including the natural history and age of onset of NPS, as well 
as genetic risk. 
 
In summary, symptoms of affective and emotional dysregulation are common harbingers 
of neurodegenerative change and progressive decline in several pre-dementia syndromes. 
Despite this, there are limited interventions to prevent and treat these symptoms and the 
ensuing dementia syndromes. Further detailed study of emotional dysregulation symptom 
domains with the MBI-C framework is critical for not only increased understanding of 
neurobiology, but also towards the development of prevention and treatment strategies for at-
risk individuals. 
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